论文部分内容阅读
近年来,无论是发达国家还是发展中国家,肺癌的发病率和死亡率均呈逐年上升趋势,已居癌症死亡的首位[1]。非小细胞肺癌(NSCLC)是肺癌的主要病理类型,占80%。即使是早期(Ⅰ期和Ⅱ期)已获得根治性切除术后患者的5年生存率也只达50%～70%,多数患者仍死于肿瘤的复发和转移[2],这些复发、转移患者无疑在首次治疗前就已有癌细胞播散到其他部位。以上现象提示人们要从微转移的角度去探讨肺癌的分期、预后及治疗模式。
In recent years, both the developed and the developing countries, the incidence of lung cancer and mortality showed a rising trend year after year, ranking first in the death of cancer [1]. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for 80%. Even in the early stage (stage I and stage II), the 5-year survival rate of patients who have undergone radical resection is only 50% -70%. Most patients still die of tumor recurrence and metastasis [2]. These recurrence and metastasis Patients undoubtedly had cancer cells disseminated to other sites before the first treatment. The above phenomenon prompts people to explore the staging, prognosis and treatment mode of lung cancer from the perspective of micrometastasis.